By modulating both pH dynamics and immune cell activity, SLC4A4 emerges as a promising therapeutic target for CRC; however, experimental studies are needed to validate its physiological impact and therapeutic efficacy further [46]. This evidence concerns the gene SLC4A4 and colorectal carcinoma.